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Noninvasive ventilation (NIV) is nowadays a medical intervention used worldwide in daily practice in many clinical settings (1). Al-most 35 years have been passed by since the first clinical studies 
on the use of NIV in the critical area (2, 3). NIV has been increasingly 
used to avoid or to serve as an alternative to invasive mechanical venti-
lation (IMV) (4). Compared with standard medical therapy (STM), and 
in some cases with IMV, NIV has been found to improve survival and re-
duce complications in selected patients with acute respiratory failure (ARF). 
The main indications are exacerbation of chronic obstructive pulmonary 
disease (COPD), cardiogenic pulmonary oedema, pulmonary infiltrates in 
immunocompromised patients, weaning of previously intubated stable pa-
tients with chronic obstructive pulmonary disease, postoperative patients, 
terminally ill patients, or as ventilatory assistance during invasive procedure 
as bronchoscopy (4). NIV has also been used in the so labelled “de novo” 
acute hypoxemic respiratory failure and acute respiratory distress syndrome 
(ARDS). Nevertheless, after many years from NIV institution in ICU (3) 
its use in hypoxemic patient not only need to be better “tuned” but it also 
seems to be decreasing compared to the last ten years (5, 6). In this patient 
population despite a satisfactory initial response (7), late failure may occur 
leading to increases in mortality rate (5). The possible causes of immediate 
failure may be due to excessive secretions, interface intolerance and agitation, 
and severe patient-ventilator asynchrony. However beyond these risk factors 
there are possibly some differences between failing in a hypercapnic or in 
hypoxemic ARF. In patients with hypoxemic ARF delayed intubation may 
lead to an increase mortality while it does not occur in COPD patients (8). 
In addition, in hypoxemic patients keep using NIV and delaying intubation 
may expose the deleterious effects on an increased transpulmonary pressure. 
The major determinant of lung stress, the transpulmonary pressure, is the re-
sult from the sum of the pressure applied to the airway by the ventilator and 
the pleural pressure generated by the patient’s spontaneous effort (9). The 
pressure generated by the respiratory muscle (respiratory effort) added to the 
level of patient-synchronized pressure support level (10) may generate high 
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DEBATE
Red, yellow or green for non-invasive mechanical ven-
tilation
Mechanical ventilation (MV) can be classified as a supportive 
treatment modality for hypoxemic respiratory failure/ARDS, 
as we do not have any data to support MV as a curative treat-
ment modality for ARDS. 
The question here is how to manage the supportive treatment 
period in ARDS. For this aim, we have the possibility of inc-
reasing the FiO2 level by several methods (such as high flow 
nasal O2 therapy ‘HFNOT’ and non-rebreathing masks) or 
the application of invasive/non-invasive MV for a period to 
allow time for curative treatments. These supportive treatment 
modalities may be alternated during the application of cura-
tive treatment agents (such as antibiotics). For example, we 
may start supportive therapy by applying HFNOT and switch 
to non-invasive ventilation according to patient needs. Later 
on, we may institute invasive MV if the patients condition de-
teriorates. We may also use adjunctive treatment options such 
as positioning the patient during these supportive treatment 
modalities. The problem is choosing the correct modality of 
support for the individual patient.
Noninvasive ventilation may be used in the initial period of sup-
portive treatment, following a period of HFNOT or invasive MV. 
It may also be used as a weaning modality of invasive MV. The 
application rules of NIN ventilation are the same for its application 
in the case of several diseases. It may have some indications (green), 
relative contraindications (yellow) or contraindications (red).
To clarify, non-invasive MV may be contraindicated in a pa-
tient with pneumonia caused by gram positive bacteria  due to 
high amount of secretions (red). However, it may be used for a 
patient with pneumocystis carinii pneumonia (green). While 
choosing the correct patient to administer MV; mild ARDS 
can be considered green, moderate ARDS may be considered 
yellow, and severe ARDS may be deemed red.
During application of non-invasive MV, the most important 
issue is to monitorize the patient. If goals such as decreasing 
FiO2 levels are reached, it may be continued. However, if the 
patients response is not sufficient, invasive ventilation should 
be instituted without delay.
A recent study in 50 countries has shown that approximately 
15% of 3022 ARDS patients were ventilated with non-in-
vasive MV, whereas 10% of them were ventilated exclusively 
with non-invasive MV (1). This 10% highlights cases in whi-
ch non-invasive MV was the sole supportive treatment moda-
lity in ARDS. To clarify it’s usage, we have to study or find the 
answer to the following questions:
Which ARDS patients should receive non-invasive MV?
When should non-invasive MV be used in ARDS?
Which mode and interface should be used during non-inva-
sive MV in ARDS?  
How can we prevent intubation delay in patients with ARDS 
during usage of non-invasive MV? 
By answering these questions, we will be able to decide if the 
use of non-invasive MV is green, yellow or red for the indivi-
dual patient.
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tidal volumes that are far from the suggested “safe” level of tidal 
volume suggested to protect the lung (11). In addition the level of 
PEEP may be insufficient to recruit consolidated lung areas (12, 
13). This in turn may cause a “self induced ventilation lung injury 
(14). Last but not least, it has been recently found that to improve 
the outcome in ARDS patients, one needs to identify potential-
ly modifiable factors associated with mortality. Higher positive 
end expiratory pressure (PEEP), lower peak, plateau, and driving 
pressures, and lower respiratory rate seem to be associated with 
improved survival from ARDS (15). Carteaux et al. (16) found 
that expired tidal volume was one of the factors determining NIV 
failure. In their study they found that patients with a tidal volume 
above 9.5 mL kg-1 of predicted bodyweight had increased risk of 
NIV failure. Interestingly, the relationship between NIV success or 
failure and expired tidal volume was observed only among patients 
with moderate-to-severe hypoxaemia (PaO2/FiO2≤200), and was 
not found in patients with milder (PaO2/FiO2>200) degrees of hy-
poxaemia (17). Frat et al. (18) found that the use high-flow nasal 
cannula (HFNC) reduced ICU and 90-day mortality as compared 
to standard oxygen and NIV. The authors speculated that the 
greater mortality with NIV might have been related to the use of 
tidal volumes greater than 9 mL kg-1, predisposing to ventilator-in-
duced lung injury (VILI). However, NIV was used intermittently 
and not continuously. The level of noninvasive pressure-support 
was only of 8±3 cmH2O of water, a PEEP only of 5±1 cmH2O. 
In addition it can be hypothesized that the use of other interfaces 
as helmets could have increase patient tolerability and time on 
NIV (19). Patel et al. (19) found that among patients with ARDS, 
treatment with helmet NIV resulted in a significant reduction of 
intubation rates. There was also a statistically significant reduc-
tion in 90-day mortality with helmet NIV. Nevertheless, although 
NIV failure seemed not to longer associated with higher mortality 
rate suggesting improved patient selection (13). Bellani et al. (20) 
found that NIV failure occurred in 22.2% of mild, 42.3% of mod-
erate and 47.1% of patients with severe ARDS. Hospital mortality 
in patients with NIV success and failure was 16.1% and 45.4%, 
respectively. NIV use was independently associated with increased 
ICU (HR 1.446-95% CI 1.159-1.805), but not hospital mortal-
ity. In a propensity-matched analysis, ICU mortality was high-
er in NIV than invasively ventilated patients with a PaO2/FiO2 
lower than 150 mmHg. Among immunocompromised patients 
admitted to the ICU with hypoxemic ARF, early NIV compared 
with oxygen therapy alone did not reduce 28-day mortality (21). 
However the median durations of NIV were 8 hours (interquartile 
range [IQR], 4-11) in the first 24 hours, 6 hours (IQR, 4-8) on 
day 2, and 5 hours (IQR, 3-7) on day 3. Overall, in the first 72 
hours the patients received NIV for a median time of 19 hours 
only, potentially too few for NIV to be effective in reducing the 
intubation rate (9). The results of the post-hoc analysis study of 
Frat et al. (22) indicates that oxygen delivery through HFNC was 
associated with lower mortality and a lower risk of IMV compared 
with NIV in immunocompromised patients. However, although 
the patients were ventilated with 7-10 mL kg-1 of expired tidal 
volume, the amount of tidal volume that reached the lungs was 
probably not more than 5-8 mL kg-1 of bodyweight because of 
dead space thus making unlikely to lead to substantial likelihood 
of developing VILI (17). In conclusion, NIV in in hypoxemic pa-
tients still remain a hot topic. Although clinicians should be aware 
of the possible harmful effects of using NIV in hypoxemic patients 
there are still many issues to discuss. Among them the experience 
and familiarity to NIV use, which hypoxemic patient do we have 
to prefer to undergo NIV (i.e. ARDS vs non ARDS), which pa-
tients should need immediate IMV, inspiratory synchronization 
especially when high VT is undesirable Maybe, we can reason in 
another way starting a new soccer game: late vs early extubation 
(using NIV as tool to early extubate our patients) in hypoxemic 
patients to prevent IMV complications (23-25). 
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